Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPB vs IV Lidocaine in Breast Cancer Surgery
NCT06490718Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, triple-blind trial of Lidocaine Hydrochloride Injection, without epinephrine in postoperative pain (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoints: Quality of Recovery-15 at 24 hours and Area under the curve of postoperative pain at 24 hours. Started Oct 2024; status: completed.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06490718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490718.